Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Cantor Fitzgerald 

Curis Inc. diskutieren

Curis Inc.

WKN: A2JMX7 / Symbol: CRIS / Name: Curis / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,36 €
-8,09 %

Einschätzung Buy
Rendite (%) -26,36 %
Kursziel 2,80
Veränderung
Endet am 07.09.24

Curis, Inc. (NASDAQ: CRIS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
Ratings data for CRIS provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,79 %
Kursziel 5,65
Veränderung
Endet am 25.09.24

Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for CRIS provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 23,91
Veränderung
Endet am 17.11.24

Curis, Inc. (NASDAQ: CRIS) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $26.00 price target on the stock.
Ratings data for CRIS provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 24,10
Veränderung
Endet am 09.02.25

Curis, Inc. (NASDAQ: CRIS) had its price target lowered by analysts at HC Wainwright from $51.00 to $26.00. They now have a "buy" rating on the stock.
Ratings data for CRIS provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 24,18
Veränderung
Endet am 08.05.25

Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Ratings data for CRIS provided by MarketBeat

Curis, Inc. (NASDAQ: CRIS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for CRIS provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 23,92
Veränderung
Endet am 15.05.25

Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $26.00 price target on the stock.
Ratings data for CRIS provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 23,89
Veränderung
Endet am 15.05.25

Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $26.00 price target on the stock.
Ratings data for CRIS provided by MarketBeat